FGF19 Polyclonal primary antibody
- Known as:
- FGF19 Polyclonal captor (anti-)
- Catalog number:
- PA1476
- Product Quantity:
- 100μg
- Category:
- -
- Supplier:
- Lunginov
- Gene target:
- FGF19 Polyclonal primary antibody
Related genes to: FGF19 Polyclonal primary antibody
- Gene:
- FGF19 NIH gene
- Name:
- fibroblast growth factor 19
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-06
- Date modifiied:
- 2016-10-05
Related products to: FGF19 Polyclonal primary antibody
Related articles to: FGF19 Polyclonal primary antibody
- This study characterized the genomic profile of esophageal squamous cell carcinoma (ESCC) via circulating tumor DNA (ctDNA) to identify predictive biomarkers for efficacy of definitive radiotherapy combined with systemic therapy. In this prospective cohort of 40 ESCC patients, 7 tumor tissues and 71 serial plasma samples were analyzed using a 340-gene panel. TP53 (45%) and PIK3CA (12.5%) were the most frequent SNVs, followed by NOTCH1/2 (7.5%). The 11q13.2-13.4 amplification (including CCND1/FGF19) occurred in 12.5% of cases. TP53 mutation rate was significantly higher in cT4 than cT2-3 stages (60% vs. 20%, p = 0.010). Notably, patients with persistent TP53 positivity posttreatment had significantly shorter PFS than those converting to negativity (HR = 5.090, p = 0.035); the 2-year PFS rates were 33.3% vs. 75%, respectively, with OS showing a borderline difference (p = 0.053). Posttreatment ctDNA-based minimal residual disease (MRD) positivity was 18.8%, correlating with a trend toward worse PFS (HR = 3.027, p = 0.067). Among the 31 patients with paired pre- and post-treatment plasma samples, the positive detection rate of nucleosome-positioning (left-shifted profile) decreased from 67.9% at baseline to 35.7% after treatment (χ = 5.793, p = 0.016). This work based on plasma ctDNA profiling demonstrated that posttreatment clearance of TP53 mutations may represent a favorable prognostic biomarker in ESCC treated with definitive radiotherapy and systemic therapy. ctDNA-derived MRD status and nucleosome positioning constitute promising non-invasive biomarkers for treatment response monitoring and risk stratification for ESCC. Trial Registration:This study was registered with the Chinese Clinical Trial Registry (ChiCTR) on December 6, 2019 (Registration No. ChiCTR1900027936). - Source: PubMed
Publication date: 2026/09/30
Liu ShutangWang QiHan ChunLi XiaoningCheng RutianLiu LihongDong HuaRen XuejiaoZhen ShumanWang Lan - This work aimed to investigate the effects of three structurally distinct soluble polysaccharides, β-glucan, arabinoxylan (AX), and pectin (Pectin), on hepatic lipid metabolism, gut endocrine-related markers, gut microbiota and associated metabolites in laying hens during late-laying period. A total of 288 Jingfen No. 6 laying hens (63-week-old, 1,094.3 ± 8.4 g, P > 0.05) were randomly allocated to four dietary treatments, each with eight replicates and 9 hens per replicate: the basal diet (control, CON) or the CON diet supplemented with 2 g/kg of Pectin, AX, or β-glucan. One week of pre-feeding, followed by 8-week formal trial period. During weeks 1-4, Pectin and β-glucan supplementation significantly increased laying rate and egg mass (P < 0.05), whereas AX supplementation had no significant effect on these production traits. At week 8, β-glucan significantly enhanced eggshell strength, whereas AX reduced albumen height and Haugh unit (P < 0.05). Further, both polysaccharides significantly reduced hepatic triglyceride (TG) content and lipid deposition at week 4 (P < 0.05), and these effects persisted to week 8 in the β-glucan and Pectin groups. The results further revealed that Pectin and β-glucan upregulated genes related to intestinal endocrine markers including fibroblast growth factor 19 (FGF19), 5-hydroxytryptamine (5-HT), glucagon-like peptide 1 (GLP-1), and ghrelin at week 4 (P < 0.05), whereas only β-glucan maintained elevated FGF19 expression at week 8 (P < 0.01). Further, correlation analysis revealed that Faecousia abundance was positively associated with duodenal 5-HT2A expression and lipid-related metabolites sitosterol metabolite and 5-oxo-eicosatetraenoic acid, but negatively correlated with plasma TG (P < 0.05). Similarly, Ligilactobacillus showed positive associations with short-chain fatty acids (SCFA) and negative associations with hepatic TG content (P < 0.01). These findings demonstrate that dietary β-glucan and Pectin alleviate hepatic lipid accumulation, which were accompanied by remodeling the gut microbiota, enhancing intestinal endocrine-related signaling, and modulating hepatic lipid metabolism. Taken together, this work demonstrates that polysaccharides with distinct structural characteristics exert differential regulatory effects, and identifies specific polysaccharides as potential nutritional modulators for remodeling the gut microbiota and associated metabolites and alleviating hepatic lipid accumulation in aged laying hens. - Source: PubMed
Publication date: 2026/09/21
Wang MengAmevor Felix KwameCao XikangLi XiaobingYue XinhuiLyu XinranJiao HongchaoWang XiaojuanZhao JingpengLi HaifangLiu MinLin Hai - β-klotho (KLB), the obligate co-receptor for fibroblast growth factor (FGF) 19 and 21 signalling, has emerged as a therapeutic target for metabolic disease. Current understanding of KLB function is based largely on germline knockout mouse models, where developmental abnormalities obscure its function in adult physiology. Here, we used somatic hepatocyte-specific gene editing in adult mice to define hepatic KLB function. - Source: PubMed
Publication date: 2026/09/22
Aaldijk Alexandra SVerzijl Cristy R CHovingh Milaine VHuijkman Nicolette C ASmit MariekeKloosterhuis Niels JMulder Niels LHavinga RickGerding AlbertBos TrijnieKoster Mirjamde Graaf MariskaWolters Justina Cvan de Sluis BartStruik DickyJonker Johan W - The pregnane X receptor (Pxr; Nr1i2) plays a role in metabolic regulation. However, its contribution to systemic energy homeostasis under physiological conditions remains unclear. Here, we investigated the metabolic consequences of Nr1i2 deficiency in chow-fed mice. - Source: PubMed
Publication date: 2026/09/19
Benoit BérengèreJalabert AudreyMeugnier EmmanuelleChanon StéphanieVieille-Marchiset AurélieBeau AlicePesenti SandraLoizon EmmanuelleVitalis OrianeBendridi NadiaNawrot MargauxMakki KassemLe Magueresse-Battistoni BrigitteRieusset JenniferMichalski Marie-CarolineRainteau DominiqueChikh KarimVidal HubertRuzzin Jérôme - Oral cavity squamous cell carcinoma (OCSCC) is a common epithelial malignancy for which site-specific biomarkers with proven prognostic utility remain limited. In this study, we present one of the largest single-center, site-specific molecular analyses of OCSCC to date. Using two separate versions of multigene next-generation sequencing (NGS), we sought to identify a focused set of clinically actionable and widely accessible biomarkers that could support diagnosis, prognostication, and therapeutic decision-making. Our findings highlight the potential of a limited molecular panel to capture key prognostic information, supporting a more accessible and scalable approach to precision oncology in OCSCC. - Source: PubMed
Publication date: 2026/09/18
Afkhami MichelleHaghighi NMa HReyes AFei FDyer TTelatar MArias-Romero JHaghighi YMehrazma AMassarelli EBakkar RTizro PBell DVillaflor V M